TAK

Takeda Pharmaceutical Company Limited: FY2025 Annual Report Summary (Form 20-F)

Business Context and Reporting Period

This summary covers the fiscal year ended March 31, 2025, for Takeda Pharmaceutical Company Limited, a global biopharmaceutical company headquartered in Japan. The company operates across six key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, Vaccines, and Neuroscience. Takeda reported revenue of JPY 4,581.6 billion for the period, representing a 7.5% increase on an actual exchange rate (AER) basis and a 2.9% increase on a constant exchange rate (CER) basis compared to the prior year.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth Drivers: Growth was driven by strong performance in GI (ENTYVIO +14.1%), Rare Diseases (TAKHZYRO +24.9%), PDT (Immunoglobulins +17.6%), and Oncology (FRUZAQLA +375.7%).
• Revenue Declines: The Neuroscience segment declined 9.8% primarily due to generic erosion of VYVANSE/ELVANSE (-17.2%) following patent expiration in the U.S. in August 2023.
• Operating Profit Surge: Operating profit increased significantly (+60.0%) due to revenue growth and a reduction in impairment charges compared to FY2024. FY2024 included significant impairments for ALOFISEL and EXKIVITY.
• Net Profit Decline: Despite higher operating profit, Net Profit declined 25.1% due to a one-time tax benefit of JPY 63.5 billion recorded in FY2024 (related to an Irish tax settlement) which was not repeated in FY2025, and higher tax expenses in the current year.
• Restructuring: The company recorded JPY 128.1 billion in restructuring expenses in FY2025 related to an enterprise-wide efficiency program announced in May 2024.
• Divestitures: Takeda completed the sale of its joint venture with Teva in Japan, recognizing a gain and receiving proceeds of JPY 56.5 billion.

Guidance, Outlook, and Risks

• Outlook: Management expects continued growth from "Growth & Launch Products" (e.g., ENTYVIO, TAKHZYRO, FRUZAQLA). The company anticipates filing for FDA approval of rusfertide and Phase 3 readouts for oveporexton and zasocitinib in the coming fiscal year.
• Dividend Policy: Takeda intends to return capital to shareholders with an annual dividend of JPY 200 per share for the fiscal year ending March 31, 2026 (up from JPY 196 in FY2025).
• Key Risks:
  • Patent Expirations: Continued erosion of VYVANSE sales and potential future erosion of ENTYVIO and other key products.
  • Regulatory & Pricing: Pricing pressures in the U.S. (Inflation Reduction Act, potential "Most Favored Nation" pricing) and Japan (NHI price revisions).
  • Development Risks: Recent clinical trial failures for soticlestat (TAK-935) and the withdrawal of Alofisel marketing authorization.
  • Supply Chain: Dependence on third-party suppliers for raw materials and plasma, with risks related to geopolitical tensions and tariffs.

Investor Verification Checklist

• Core vs. GAAP Profit: Verify the reconciliation between reported Net Profit (JPY 107.9B) and Core Net Profit (JPY 775.6B) to understand the impact of amortization, impairments, and restructuring.
• VYVANSE Trajectory: Monitor the rate of decline in VYVANSE sales as generic competition intensifies in the U.S. market.
• Debt Reduction: Confirm the trajectory of Adjusted Net Debt reduction and compliance with financial covenants (Adjusted Net Debt/Adjusted EBITDA ratio).
• Restructuring Costs: Track the execution of the JPY 128.1 billion restructuring program and its impact on future operating margins.
• Pipeline Milestones: Watch for Phase 3 data readouts for key assets like zasocitinib (TAK-279) and oveporexton (TAK-861) to assess future growth potential.
• Tax Rate Volatility: Review the effective tax rate, noting the absence of the one-time FY2024 tax benefit and the impact of OECD Pillar Two taxes.